Tag: Liver cancer

New treatment option for liver cancer

Data presented at the ESMO Congress 2024 (Barcelona, 13–17 September) shows that adding Lenvatinib (tablets) and Pembrolizumab (immunotherapy infusion) to standard treatment has the potential to improve prognosis.

The trial was done in intermediate stage patients.

Adding the combination of Lenvatinib and Pembrolizumab to the other standard treatment TACE seems to work.

The response rates are better with combination and early results are promising but the data is still immature.

Another caveat is that this combination was previously tested in the advanced setting. The combination of Lenvatinib and Pembrolizumab did NOT improve survival in the advanced cancer patient group.

Disclaimer: Please note – This blog is NOT medical advice. This blog is NOT a expert medical opinion on various topics. This blog is purely for information only and do check the sources where cited. Please DO consult your own doctor to discuss concerns and options relevant to you. The views expressed in this blog are NOT, in any way whatsoever, intended to be a substitute for professional advice. The blog is NOT previewed, commissioned or otherwise endorsed, in any way, by any organisation that the author is associated with. The views expressed in this blog likely represents some of the author’s personal views held at the time of drafting the blog and MAY CHANGE overtime, particularly when new evidence comes to light.

New immunotherapy treatment option for Liver cancer

Immunotherapy has dramatically improved the prognosis of skin cancer patients and has made significant improvement in prognosis of kidney, lung, uterus and bladder cancer patients .

Advanced liver cancer is notoriously difficult to treat and prognosis is often poor.

Now a widely used combination immunotherapy therapy treatment has been found to improve the prognosis of liver cancer patients.

Patients with inoperable, previously untreated, liver cancer had significantly longer overall survival with the combination of nivolumab plus ipilimumab compared with former standard-of-care with lenvatinib or sorafenib.

Doublet Immunotherapy (nivolumab plus ipilimumab ) is a standard of care now in primary liver cancer ( HCC: hepato cellular carcinoma ).

References

1. ASCO 2024. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. Abstract LBA4008

Disclaimer: Please note – This blog is NOT medical advice. This blog is NOT a expert medical opinion on various topics. This blog is purely for information only and do check the sources where cited. Please DO consult your own doctor to discuss concerns and options relevant to you. The views expressed in this blog are NOT, in any way whatsoever, intended to be a substitute for professional advice. The blog is NOT previewed, commissioned or otherwise endorsed, in any way, by any organisation that the author is associated with. The views expressed in this blog likely represents some of the author’s personal views held at the time of drafting the blog and MAY CHANGE overtime, particularly when new evidence comes to light.